holmes schreef op 21 september 2023 21:19:
[...]
Other updates 21 september 2023
Pharming shortlisted for prestigious Scrip awards 2023Pharming shortlisted in two categories, including “Biotech Company of the Year” and “Best New Drug”
The Scrip awards, now in its 19th year, brings over 400 industry leaders together to celebrate and recognize the very best innovations and achievements in global biopharma. This year, Pharming has been shortlisted in two categories including, “Biotech Company of the Year” and “Best New Drug”.
The Biotech Company of the Year award honours outstanding achievement by biotech companies within the past year. The Best New Drug Award recognises excellence in pharmaceutical development, with the product being approved in its first market worldwide and representing the best therapeutic advancement in its area.
These are the second awards Pharming has been shortlisted for in 2023. Sijmen de Vries, CEO of Pharming Group, won CEO of the Year at the Mediscience Awards in June 2023.
The awards ceremony will take place in London on November 16.
To learn more about the Scrip Awards 2023, please click here.
www.pharming.com/nl/node/420The Best New Drug Award recognizes excellence in pharmaceutical development. Launching innovative new products is the most important function of the industry, and a successful new drug launch marks the culmination of years of risky and expensive R&D. In this category, the judges will be looking for the small-molecule or biological product that was approved in its first market worldwide during the qualifying period that represents the best therapeutic advance in its area.
FINALISTS
Eisai’s Leqembi (lecanemab) for Alzheimer's disease
Eli Lilly’s Olumiant (baricitinib) for severe alopecia areata
Ferring Pharmaceuticals’ Rebyota (fecal microbiota, live) for recurrent Clostridioides difficile infection
Gamida Cell’s Omisirge (Omidubicel-olv) for use in hematopoietic stem cell transplants
Genmab and AbbVie’s Epkinly (epcoritamab) for diffuse large B-cell lymphoma
Pharming's Joenja (leniolisib) for activated phosphoinositide 3-kinase delta (PI3Kd) syndromeReata Pharmaceuticals' Skyclarys (omaveloxolone) for Friedreich's ataxia
Stemline Therapeutics (Menarini)’s Orserdu (elacestrant) for breast cancer
The biotech industry’s entrepreneurial spirit and cutting-edge science have transformed the research and development of medicines in the past few decades. This Award honours outstanding achievement by biotech companies over the qualifying 12 months.
FINALISTS
Affini-T Therapeutics
Calliditas Therapeutics
Complement Therapeutics
Ionis Pharmaceuticals
MoonLake Immunotherapeutics
PharmingPTC Therapeutics
Verona Pharma